Dixon Hubard Feinour & Brown Inc Eli Lilly & CO Transaction History

Dixon Hubard Feinour & Brown Inc

$842 Million
Q2 2022

A detailed history of Dixon Hubard Feinour & Brown Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Dixon Hubard Feinour & Brown Inc holds 19,034 shares of LLY stock, worth $14.9 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares

19,034

Previous 19,698 3.37%

Holding current value

$14.9 Million

Previous $5.64 Million 9.4%

% of portfolio

0.73%

Previous 0.56%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$278.73 - $327.27 $185,076 - $217,307	-664 Reduced 3.37%	19,034 $6.17 Million
Q1 2022 May 09, 2022	SELL	$234.69 - $291.66 $19,948 - $24,791	-85 Reduced 0.43%	19,698 $5.64 Million
Q4 2021 Jan 10, 2022	SELL	$224.85 - $279.04 $2,023 - $2,511	-9 Reduced 0.05%	19,783 $5.46 Million
Q3 2021 Oct 19, 2021	SELL	$221.6 - $272.71 $268,579 - $330,524	-1,212 Reduced 5.77%	19,792 $4.57 Million
Q2 2021 Aug 23, 2021	SELL	$180.55 - $233.54 $106,524 - $137,788	-590 Reduced 2.73%	21,004 $4.82 Million
Q1 2021 May 14, 2021	SELL	$164.32 - $212.72 $454,837 - $588,808	-2,768 Reduced 11.36%	21,594 $4.03 Million
Q3 2020 Nov 12, 2020	SELL	$146.22 - $169.13 $171,808 - $198,727	-1,175 Reduced 4.6%	24,362 $3.61 Million
Q2 2020 Jul 31, 2020	SELL	$136.42 - $164.18 $92,765 - $111,642	-680 Reduced 2.59%	25,537 $4.15 Million
Q1 2020 May 15, 2020	SELL	$119.05 - $147.35 $57,501 - $71,170	-483 Reduced 1.81%	26,217 $3.64 Million
Q4 2019 Feb 14, 2020	SELL	$106.92 - $132.43 $10,371 - $12,845	-97 Reduced 0.36%	26,700 $3.51 Million
Q3 2019 Nov 13, 2019	SELL	$106.79 - $116.16 $20,396 - $22,186	-191 Reduced 0.71%	26,797 $3 Million
Q2 2019 Aug 14, 2019	BUY	$110.79 - $129.32 $52,403 - $61,168	473 Added 1.78%	26,988 $2.99 Million
Q1 2019 May 17, 2019	BUY	$111.31 - $131.02 $53,428 - $62,889	480 Added 1.84%	26,515 $3.44 Million
Q3 2018 Nov 06, 2018	BUY	$85.86 - $107.31 $17,172 - $21,462	200 Added 0.77%	26,035 $2.79 Million
Q2 2018 Jul 25, 2018	SELL	$75.7 - $86.88 $57,532 - $66,028	-760 Reduced 2.86%	25,835 $2.21 Million
Q1 2018 May 14, 2018	SELL	$74.21 - $87.6 $51,575 - $60,881	-695 Reduced 2.55%	26,595 $2.06 Million
Q4 2017 Feb 20, 2018	SELL	$81.94 - $87.89 $20,485 - $21,972	-250 Reduced 0.91%	27,290 $2.31 Million
Q3 2017 Nov 08, 2017	BUY	$77.07 - $85.54 $2.12 Million - $2.36 Million	27,540	27,540 $2.36 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $744B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dixon Hubard Feinour & Brown Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dixon Hubard Feinour & Brown Inc with notifications on news.

Account

Dixon Hubard Feinour & Brown Inc Eli Lilly & CO Transaction History